Oral Mucositis Pipeline

 

 

Involved pharmaceutical companies in the Oral Mucositis market are Galera Therapeutics, Soligenix, Monopar Therapeutics, Enzychem Lifesciences, Innovation Pharmaceuticals, Spherium Biomed, and others.

 

DelveInsight’s “Oral Mucositis Pipeline” highlights the details around Oral Mucositis, painful inflammation, and ulceration of the mucous membranes lining the mouth, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer. 

 

The Oral Mucositis report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The report also highlights the unmet needs concerning the development of Oral Mucositis.

 

Some of the key highlights of the Oral Mucositis Pipeline report

 

  • Galera Therapeutics initiated a study titled “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, and Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer”.
  • Avasopasem manganese (GC4419) is a highly selective and potent small molecule dismutase mimetic that closely mimics the activity of human superoxide dismutase enzymes.
  • Key companies involved in the Oral Mucositis Pipeline are Galera Therapeutics, Soligenix, Monopar Therapeutics, Enzychem Lifesciences, Innovation Pharmaceuticals, Spherium Biomed, and others.

 

Request for Sample @ Oral Mucositis Pipeline Insights

 

Oral Mucositis is a painful inflammation and ulceration of the mucous membranes lining the mouth, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer. Mucositis leads to several problems including pain, problems with nutrition and being unable to eat, and a higher chance of infection due to open sores. About 40% of people undergoing regular cancer therapy will get Oral Mucositis.

 

Oral Mucositis Emerging Therapies: Drug Profile

 

 

  • Cooral System: BrainCool

 

 

Cooral is a single-use oral cooling device that links to a portable cooling system and cools the oral mucosa. Cooral is equipped with an ECU200 water cooling unit that circulates 8°C water into an attached mouthpiece which is inserted into the patient’s mouth.

 

 

  • CareMin650: NeoMedLight

 

CareMin650 previously ONCORED from NeoMedLight is a device using the light-emitting fabric Lightex – unique patented technology – emitting light through woven optic fibers.

 

 

  • Validive: Monopar Therapeutics

 

 

Validive (clonidine Lauriad) is a mucoadhesive tablet based on the Lauriad technology that delivers high concentrations of an anti-inflammatory active principle (clonidine) directly in the oral cavity, the site of irradiation in the treatment of head and neck cancer.

Know More Information @ Oral Mucositis Pipeline Drugs

 

Key Pipeline Therapies along with companies

 

  • GC4419the: Galera Therapeutics
  • SGX942: Soligenix
  • Clonidine HCl MBT: Monopar Therapeutics
  • EC-18: Enzychem Lifesciences
  • Brilacidin: Innovation Pharmaceuticals
  • Melatonin oral gel: Spherium Biomed

 

Oral Mucositis Therapeutics Assessment

 

By Product Type

  • Mono
  • Combination

 

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

 

By Route of Administration

  • Intravenous
  • Inhalation
  • Oral
  • Subcutaneous 

 

By Molecule Type 

  • Small Molecule 
  • Gene Therapy
  • Stem Cell Therapy

 

By Mechanism of Action

  • Protease Inhibitors
  • Immunomodulatory

 

By Targets

  • Protease 
  • Immune System

 

Contact Here for More Information @ Oral Mucositis Pipeline Assessment

 

Scope of the Oral Mucositis Pipeline Report

 

  • Coverage- Global
  • Key Market Players- Galera Therapeutics, Soligenix, Monopar Therapeutics, Enzychem Lifesciences, Innovation Pharmaceuticals, Spherium Biomed, and many others.
  • Key Oral Mucositis Pipeline Therapies-  GC4419, SGX942, Clonidine HCl MBT, EC-18, Brilacidin, Melatonin Oral Gel, and many others.

 

Following is the Table of content of the Oral Mucositis Pipeline Report

1 Report Introduction
2 Oral Mucositis
3 Oral Mucositis Current Treatment Patterns
4 Oral Mucositis – DelveInsight’s Analytical Perspective
5 Therapeutic Assessment
6 Oral Mucositis Late Stage Products (Phase-III)
7 Oral Mucositis Mid Stage Products (Phase-II)
8 Early Stage Products (Phase-I)
9 Pre-clinical Products and Discovery Stage Products
10 Inactive Products
11 Dormant Products
12 Oral Mucositis Discontinued Products
13 Oral Mucositis Product Profiles
14 Oral Mucositis Key Companies
15 Oral Mucositis Key Products
16 Dormant and Discontinued Products
17 Oral Mucositis Unmet Needs
18 Oral Mucositis Future Perspectives
19 Oral Mucositis Analyst Review
20 Appendix
21 Report Methodology

 

Know more of what’s covered in the Oral Mucositis Pipeline Assessment report

 

Key Questions Answered in the Oral Mucositis report-

 

  • What are the current options for Oral Mucositis treatment?
  • How many companies are developing therapies for the treatment of Oral Mucositis? 
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Oral Mucositis?
  • How many Oral Mucositis emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Oral Mucositis?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Oral Mucositis market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Oral Mucositis?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Oral Mucositis therapies? 
  • What are the clinical studies going on for Oral Mucositis and their status?
  • What are the results of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Oral Mucositis? 
  • How many patents are granted and pending for the emerging therapies for the treatment of Oral Mucositis?

 

Request for demo @ Oral Mucositis Pipeline and get a walk-through of our report

 

Related Reports

 

 

DelveInsight’ s Cervical Cancer Market Insights, Epidemiology and Market Forecast – 2030 report.

 

 

DelveInsight’ s Prostate cancer Market Insights, Epidemiology and Market Forecast – 2030 report.

DelveInsight’s Cancer Anorexia Market Insights, Epidemiology and Market Forecast – 2030 report.

 

 

DelveInsight’ s Non-Small Cell Lung Cancer – Market Insights, Epidemiology and Market Forecast – 2030 report.

Visit on our blog section-

 

 

About DelveInsight

DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.

Tags: , , , , , , , , , , , , , , ,

See Campaign: https://www.delveinsight.com/
Contact Information:
Shruti Thakur  info@delveinsight.com  +1(919)321-6187

Tags:
Financial Content, Reportedtimes, Menafn, Extended Distribution, iCN Internal Distribution, Research Newswire, English

image

Contact Information:

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187